Benlysta

Biopharmaceutical company Human Genome Sciences (NASDAQ: HGSI) agreed Monday to a $3.6 billion takeover bid by GlaxoSmithKline (NYSE: GSK). On Monday, Benzinga reported that GlaxoSmithKline was preparing for the takeover, and that it had offered roughly $14 per share. However, the deal had yet to...

Goldman Sachs has published a research report on Human Genome Sciences (NASDAQ: HGSI) after the company revealed weakened Benlysta sales in November. In the report, Goldman Sachs writes, "Benlysta November IMS sales declined by 3% on an average weekly basis over October (vs. 13% growth for October...

Human Genome Sciences (NASDAQ: HGSI) is up around 9% this morning after the company received FDA approval for its lupus drug, Benlysta. Human Genome partners with GlaxoSmithKline (NYSE: GSK) on the drug, and despite widespread expected approval of the drug, there had been concerns about labeling...

Collins Stewart published its research report on Human Genome Sciences (NASDAQ: HGSI) after the FDA announced it would delay the PDUFA on HGSI's Benlysta. In a note to clients, Collins Stewart writes, "removes the risk of a Class 2 resubmission with a 6-month review period. We continue to expect...

J.P. Morgan analysts Cory Kasimov and Mona Ashiya reiterated their Overweight rating for shares of Human Genome Sciences, Inc. (Nasdaq: HGSI) The two analysts believed that the failure of a recent Phase 2 non-small cell lung cancer trial would not have a significant impact on Human Genome Sciences...